Cargando…

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shearer, R. J., Davies, J. H., Dowsett, M., Malone, P. R., Hedley, A., Cunningham, D., Coombes, R. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971817/ https://www.ncbi.nlm.nih.gov/pubmed/2201397

Ejemplares similares

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992)

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
por: Bonnefoi, H. R., et al.
Publicado: (1996)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
por: Dowsett, M., et al.
Publicado: (1988)

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.
por: Ponder, B. A., et al.
Publicado: (1984)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

Reply: aromatase inhibition in advanced breast cancer: no conclusive evidence of efficacy differences
por: Sainsbury, R
Publicado: (2005)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1991)

Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
por: Sainsbury, R
Publicado: (2004)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
por: Macaulay, V. M., et al.
Publicado: (1994)

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.
por: Stein, R. C., et al.
Publicado: (1990)

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
por: Miller, Christopher A., et al.
Publicado: (2016)

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
por: López-Knowles, Elena, et al.
Publicado: (2014)

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
por: Gibb, Fraser W., et al.
Publicado: (2016)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Modelling inhibition of avian aromatase by azole pesticides
por: Saxena, A.K., et al.
Publicado: (2015)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition
por: Ellis, Matthew J., et al.
Publicado: (2012)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome
por: Grindstad, Thea, et al.
Publicado: (2016)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Prognostic significance of serum prolactin levels in advanced breast cancer.
por: Dowsett, M., et al.
Publicado: (1983)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase.
por: Zarn, Jürg A, et al.
Publicado: (2003)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
por: Freedman, OC, et al.
Publicado: (2009)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Collecting, Communicating and Using Information
por: Jones, R B, et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_g4jhmaidnj1tk80iofvmb672i9